# Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

> **NCT05405114** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 96 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** NDec - oral decitabine-tetrahydrouridine
- **DRUG:** HU - Hydroxyurea
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05405114
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-07
- **Primary completion:** 2025-07-24
- **Final completion:** 2025-07-24
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05405114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05405114, "Research Study Investigating How Well NDec Works in People With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05405114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*